CN114634934A - 特异识别金葡菌肠毒素b的核酸适配体3-2和2-27的序列及应用 - Google Patents
特异识别金葡菌肠毒素b的核酸适配体3-2和2-27的序列及应用 Download PDFInfo
- Publication number
- CN114634934A CN114634934A CN202011480102.XA CN202011480102A CN114634934A CN 114634934 A CN114634934 A CN 114634934A CN 202011480102 A CN202011480102 A CN 202011480102A CN 114634934 A CN114634934 A CN 114634934A
- Authority
- CN
- China
- Prior art keywords
- staphylococcus aureus
- aptamers
- aureus enterotoxin
- aptamer
- enterotoxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091023037 Aptamer Proteins 0.000 title claims abstract description 41
- 241000191967 Staphylococcus aureus Species 0.000 title claims abstract description 31
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 12
- 229960002685 biotin Drugs 0.000 claims abstract description 6
- 235000020958 biotin Nutrition 0.000 claims abstract description 6
- 239000011616 biotin Substances 0.000 claims abstract description 6
- 238000011160 research Methods 0.000 claims abstract description 6
- 238000001514 detection method Methods 0.000 claims abstract description 5
- 206010041925 Staphylococcal infections Diseases 0.000 claims abstract description 4
- 238000011161 development Methods 0.000 claims abstract description 4
- 238000009509 drug development Methods 0.000 claims abstract description 4
- 208000015339 staphylococcus aureus infection Diseases 0.000 claims abstract description 4
- 238000000338 in vitro Methods 0.000 claims description 5
- 108020004414 DNA Proteins 0.000 claims description 2
- 102000053602 DNA Human genes 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 claims 1
- 108020004682 Single-Stranded DNA Proteins 0.000 claims 1
- 238000010170 biological method Methods 0.000 claims 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 claims 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 claims 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 abstract 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 abstract 1
- 229960005156 digoxin Drugs 0.000 abstract 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 abstract 1
- 238000005406 washing Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 238000010494 dissociation reaction Methods 0.000 description 6
- 230000005593 dissociations Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000012528 membrane Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 206010016952 Food poisoning Diseases 0.000 description 2
- 208000019331 Foodborne disease Diseases 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 231100000617 superantigen Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 206010010725 Conjunctival irritation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- -1 clinical diagnosis Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000037890 multiple organ injury Diseases 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
- G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了属于分子生物医学技术领域的两条特异识别金葡菌肠毒素B的核酸适配体3‑2、2‑27的序列和应用。本发明涉及核酸适配体3‑2、2‑27特异的序列,采用5’端或3’端修饰、标记(如同位素、生物素或者地高辛等)的方法,检测到核酸适配体3‑2、2‑27能够特异识别金葡菌肠毒素B。核酸适配体3‑2、2‑27作为试剂盒的组成部分或者检测指标,用于金葡菌肠毒素B的检测或者抗金葡菌感染发生、发展、进程相关的基础研究及靶向药物研制等。
Description
发明领域:
本发明涉及两条特异识别金葡菌肠毒素B的核酸适配体3-2、2-27的序列和修饰,以及 修饰后的3-2、2-27在识别金葡菌肠毒素B方面的应用。本发明涉及3-2、2-27在生物医药 方面的应用。3-2、2-27作为试剂盒的组成部分或者检测指标,用于金葡菌肠毒素B的检测 或者抗金葡菌感染发生、发展、进程相关的基础研究及靶向药物研制等。
背景技术:
指数富集的配基系统进化技术,简称SELEX(Systematic Evolution of Ligandsby EXponential Enrichment)技术,是近十几年兴起并迅速得到发展的高通量生物文库筛选技术。 应用大容量的随机寡核苷酸文库(ssDNA文库和RNA文库),结合PCR体外扩增技术,以 指数级富集与靶分子特异结合的寡核苷酸,经过反复的体外筛选、扩增,最终获得的核酸适 配体(aptamer)基于空间结构与靶分子呈高特异性和高亲和力的结合。由于核酸适配体具有 精确识别、无免疫原性、易体外合成与修饰等优点,又称为“人工替代抗体”,在基础医学、 临床诊断与新药研发等方面具有广阔的应用前景。尤其是近年来兴起的复合靶SELEX技术, 使得对未知靶分子进行筛选成为可能,并且通过引入消减筛选步骤,能够获得特异识别两组 复合靶子中差异存在分子的核酸适配体,并能利用该配基反过来对差异靶分子进行研究,这 就为开发新型分子探针以及鉴定生物标志物开辟了新的途径。
金黄色葡萄球菌肠毒素(Staphylococcalenterotoxins,SEs)是由金黄色葡萄球菌和化脓性 链球菌分泌的超级抗原。SEs是免疫系统的有效激活剂。金黄色葡萄球菌肠毒素B(SEB)和 相关的超抗原毒素是免疫系统的有效激活剂。这些蛋白质毒素直接与抗原呈递细胞上的主要 组织相容性复合物(MHCII)类分子和T细胞受体(TCR)的特定Vβ区结合,导致单核细 胞、巨噬细胞和T淋巴细胞均被激活,引发早期的“细胞因子风暴”和大规模的多克隆T细 胞增殖。使得促炎细胞因子:肿瘤坏死因子α(TNF-α),白介素1(IL-1),IL-2,干扰素γ (IFN-γ)和巨噬细胞趋化蛋白1等大量释放,引起发热,炎症,多器官损伤,低血压和致 死性休克等疾病。SEB被美国疾病控制与预防中心(CentersforDiseaseControlandPrevention,简 称cdc)认定为B类精选制剂。SEB中毒通常是在食用加工过的肉类或奶制品后(处理和储存 不当)而引起的食物中毒。除了造成食物中毒,SEB还被用作生物战剂,吸入SEB后2小时 内可引起以下症状:头痛、肌肉疼痛、心动过速、咳嗽、恶心、呕吐、腹泻和结膜刺激。这些 形式的失能发生在毫微克水平,而微克的SEB可能是致命的。
本发明是通过SELEX技术获得了两条核酸适配体3-2、2-27。经鉴定,核酸适配体3-2、 2-27能够特异识别金葡菌肠毒素B,而不结合其他蛋白,对照核酸序列与上述蛋白均无结合, 目前虽见到文献有报道特异结合金葡菌肠毒素B的核酸适配体的相关研究报道,但是我们筛 选获得的适配体序列与文献报道的适配体序列并不一样,类似于针对同一抗原可以有不同结 合位点的抗体,由于其筛选的初始文库不同,因此针对同一靶标SEB,不同的适配体与其结 合的位点也会不同。因此本发明中的适配体3-2、2-27的序列具有独创性和新颖性。
发明内容:
本发明目的在于提出特异识别金葡菌肠毒素B的核酸适配体3-2、2-27的序列及其应用 领域,包括核酸适配体3-2、2-27作为试剂盒的组成部分或者检测指标,用于金葡菌肠毒素 B的检测或者抗金葡菌感染发生、发展、进程相关的基础研究及靶向药物研制等
本发明通过以下技术方案实现:
首先由生工公司合成P7-26序列,并在5’端或3’端修饰、标记(如生物素),然后进行应用研究:ELISA方法或滤膜-化学发光法检测3-2、2-27识别金葡菌肠毒素B。
本发明优点:
1)与蛋白类的抗体相比,核酸适配体更加稳定;核酸适配体可直接体外合成、标记,因此 不需要标记的二抗,使得操作更为简单、迅速;核酸适配体的合成成本较抗体制备成本 低,周期短。
2)本发明证实核酸适配体3-2、2-27序列特异识别金葡菌肠毒素B。因此,核酸适配体3-2、 2-27序列在生防与疾控等方面的研究相关领域中均具有广泛的应用价值和广阔的市场前 景。
附图说明:
图1 ELISA实验证实适配体3-2、2-27所结合的靶标为金葡菌肠毒素B。
图2滤膜-化学发光法实验证实适配体3-2、2-27所结合的靶标为金葡菌肠毒素B。
图3 ELISA实验证明3-2、2-27特异识别金葡菌上清中的SEB,而对照序列无结合。
图4适配体3-2与金葡菌肠毒素B结合的平衡解离常数(KD值)的测定.
图5适配体2-27与金葡菌肠毒素B结合的平衡解离常数(KD值)的测定
具体实施方式:
下面通过适配体3-2、2-27对金葡菌肠毒素B的识别来进一步描述本发明。
本发明通过以下技术方案实现:
1.通过生物素标记的3-2、2-27对金葡菌肠毒素B的特异识别来进一步描述本发明。
1.1合成3-2、2-27(序列表中SEQ ID No.1、NO.2)和无关对照序列-GP30(序列表中SEQ ID No.3),通过公司合成使3-2、2-27和GP30的5’端标记上Bio。
Bio-3-2:
5-GCAATGGTACGGTACTTCCGGGGGTGGGTGTCTGGTGTCTGGTGCATCCTGGTTGCTGTTTGTGCAAAAGTGCACGCT ACTTTGCTAA-3’
Bio-2-27:
5-GCAATGGTACGGTACTTCCGGTCTGGTTAGGTGTTGGGCATGGTGGTTGCTTTCCAAAAGTGCACGCTACTTTGCTAA -3’
Bio-GP30:
5’-GCAATGGTACGGTACTTCC(N)30CAAAAGTGCACGCTACTTTGCTAA-3’
注:N代表A、T、G、C任意一种。
2.ELISA方法鉴定生物素标记的3-2、2-27特异识别金葡菌肠毒素B
2.1将一定量的金葡菌肠毒素B融于pH 9.7的碳酸盐缓冲液中,按照100μl/孔加入到酶联 条中,4℃包被蛋白过夜;
2.2弃包被液,每孔加入100μl含2%BSA封闭液,室温封闭60min;
2.3将不同浓度的Bio-2-27、Bio-3-2和无关对照序列Bio-GP30溶解于合适体积的缓冲液中 (1×PBS-1mmolMgCl2),于100℃变性5min后立即置于冰上充分冷却;
2.4将经过变性处理后的Bio-2-27、Bio-3-2和无关对照序列(Bio-GP30文库)加入酶联条 中,使核酸适配体与包被的金葡菌肠毒素B共同孵育37℃2h;
2.5弃去孔内液体,每孔用350μl的洗涤液洗涤,重复洗涤3次,最后一次洗涤后要把孔内 液体完全甩干;
2.6每孔加入100μl按照1∶100稀释好的HRP酶,室温孵育40min,弃去孔内液体,洗板5 次,方法同上;
2.7每孔加入100μl TMB显色底物,37℃避光显色,当有明显颜色变化时,加10μl终止 液,酶联仪读数。
3.滤膜-化学发光法鉴定Bio标记的3-2、2-27对SEB的特异识别
3.1将一定量的SEB点在HAWP膜上,并室温平衡30min;
3.2将一定浓度的Bio-标记的3-2、2-27和无关对照序列(Bio-GP30文库)溶解于合适 体积的缓冲液中(1×PBS-1mmolMgCl2),于100℃变性5min后立即置于冰上充分冷却;
3.3洗膜:将上述滤膜侵泡在洗涤缓冲液中并置于摇床上缓慢摇动,共洗3次,每次2min;
3.4将上述滤膜放入加有1∶100稀释好的HRP酶缓冲液中,室温孵育40min,洗膜,方法同 上,共洗3次;
3.5上述滤膜与TMB显色液孵育5min,37℃避光显色,化学发光仪检测并留图。
4.ELISA方法鉴定生物素标记的3-2、2-27特异识别金葡菌培养上清中的肠毒素B
4.1将一定量的金葡菌培养上清融于pH 9.7的碳酸盐缓冲液中,按照100μl/孔加入到酶联 条中,4℃包被蛋白过夜;
4.2弃包被液,每孔加入100μl含2%BSA封闭液,室温封闭60min;
4.3将不同浓度的Bio-2-27、Bio-3-2和无关对照序列(Bio-GP30文库)溶解于合适体积的 缓冲液中(1×PBS-1mmolMgCl2),于100℃变性5min后立即置于冰上充分冷却;
4.4将经过变性处理后的Bio-3-2、Bio-2-27和无关对照序列(Bio-GP30文库)加入酶联条 中,使核酸适配体与包被的金葡菌肠毒素B共同孵育37℃2h;
4.5弃去孔内液体,每孔用350μl的洗涤液洗涤,重复洗涤3次,最后一次洗涤后要把孔内 液体完全甩干;
4.6每孔加入100μl按照1∶100稀释好的HRP酶,室温孵育40min,弃去孔内液体,洗板5 次,方法同上;
4.7每孔加入100μl TMB显色底物,37℃避光显色,当有明显颜色变化时,加10μl终止 液,酶联仪读数。
5、3-2、2-27与SEB蛋白结合的平衡解离常数(KD值)的测定
将100nM Bio标记的适配体溶解于上样液中(1×PBS,1mmol/L MgCl2,0.02%吐温20)进样,随后分别与最高浓度为2μM的等比稀释的不同浓度SEB溶液(上样液溶解)结合,最后用上样液解离。整个上样、结合、解离过程均在分子相互作用仪中进行。舍去偏离曲线较远的点绘制图像。适配体-SEB相互作用的曲线和解离常数(KD)为使用软件计算和绘制得到。
实验结果:
以上实验方法均证明核酸适配体3-2、2-27特异结合SEB
由图1可以得到结论:ELISA实验证明3-2、2-27特异识别SEB,而对照序列则 与SEB无结合。
由图2可以得到结论:滤膜-化学发光法实验证明3-2、2-27能够特异结合SEB, 而对照序列与SEB无结合。
由图3可以得到结论:ELISA实验证明3-2、2-27特异识别金葡菌培养上清中的SEB,而对照序列则无结合。
由图4可以得到结论:3-2与SEB结合的平衡解离常数KD值,约为1.11E-05M。
由图5可以得到结论:2-27与SEB结合的平衡解离常数KD值,约为4.55E-05M。
总之,核酸适配体3-2、2-27能够特异识别SEB,具有广泛临床应用价值。
Claims (4)
1.两条特异识别金葡菌肠毒素B的单链DNA核酸适配体3-2、2-27的序列,其特征在于,所述的核苷酸序列分别如序列表中SEQ ID No.1、No.2所示。
2.据权利要求1中所述方法,核酸适配体3-2、2-27可以是体外化学合成的,也可以是通过PCR或其他分子生物学方法制备的。
3.据权利要求1中所述方法,核酸适配体3-2、2-27的5’端或3’端可以经同位素、生物素、地高辛等标记。
4.据权利要求1中所述方法,核酸适配体3-2、2-27作为试剂盒的组成部分或者检测指标,用于金葡菌肠毒素B的检测或者抗金葡菌感染发生、发展、进程相关的基础研究及靶向药物研制等领域中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011480102.XA CN114634934B (zh) | 2020-12-16 | 2020-12-16 | 特异识别金葡菌肠毒素b的核酸适配体3-2和2-27的序列及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011480102.XA CN114634934B (zh) | 2020-12-16 | 2020-12-16 | 特异识别金葡菌肠毒素b的核酸适配体3-2和2-27的序列及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114634934A true CN114634934A (zh) | 2022-06-17 |
CN114634934B CN114634934B (zh) | 2024-04-26 |
Family
ID=81944736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011480102.XA Active CN114634934B (zh) | 2020-12-16 | 2020-12-16 | 特异识别金葡菌肠毒素b的核酸适配体3-2和2-27的序列及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114634934B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103224936A (zh) * | 2013-05-16 | 2013-07-31 | 江南大学 | 一组特异性识别金黄色葡萄球菌肠毒素a的核酸适配体 |
CN103243101A (zh) * | 2013-05-16 | 2013-08-14 | 江南大学 | 一组特异性识别金黄色葡萄球菌肠毒素c1的核酸适配体 |
CN104450712A (zh) * | 2014-04-11 | 2015-03-25 | 中国人民解放军军事医学科学院基础医学研究所 | 一种特异识别Vasorin(VASN)蛋白的寡核苷酸配基V4-2的序列和应用 |
US20150260717A1 (en) * | 2014-03-12 | 2015-09-17 | Korea Institute Of Science And Technology | Universal nucleic acid aptamers for commonly binding to various types of microorganicms and method of producing the same |
CN106636105A (zh) * | 2016-12-16 | 2017-05-10 | 中国人民解放军南京军区福州总医院 | 金黄色葡萄球菌肠毒素c2的核酸适配体c203及其筛选方法和应用 |
CN111139288A (zh) * | 2020-01-21 | 2020-05-12 | 长江师范学院 | 基于适配体识别-杂交链式反应同时检测金黄色葡萄球菌肠毒素a、b的荧光传感器 |
-
2020
- 2020-12-16 CN CN202011480102.XA patent/CN114634934B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103224936A (zh) * | 2013-05-16 | 2013-07-31 | 江南大学 | 一组特异性识别金黄色葡萄球菌肠毒素a的核酸适配体 |
CN103243101A (zh) * | 2013-05-16 | 2013-08-14 | 江南大学 | 一组特异性识别金黄色葡萄球菌肠毒素c1的核酸适配体 |
US20150260717A1 (en) * | 2014-03-12 | 2015-09-17 | Korea Institute Of Science And Technology | Universal nucleic acid aptamers for commonly binding to various types of microorganicms and method of producing the same |
CN104450712A (zh) * | 2014-04-11 | 2015-03-25 | 中国人民解放军军事医学科学院基础医学研究所 | 一种特异识别Vasorin(VASN)蛋白的寡核苷酸配基V4-2的序列和应用 |
CN106636105A (zh) * | 2016-12-16 | 2017-05-10 | 中国人民解放军南京军区福州总医院 | 金黄色葡萄球菌肠毒素c2的核酸适配体c203及其筛选方法和应用 |
CN111139288A (zh) * | 2020-01-21 | 2020-05-12 | 长江师范学院 | 基于适配体识别-杂交链式反应同时检测金黄色葡萄球菌肠毒素a、b的荧光传感器 |
Non-Patent Citations (3)
Title |
---|
DEGRASSE JA 等: "A single-stranded DNA aptamer that selectively binds to Staphylococcus aureus enterotoxin B", PLOS ONE * |
李慧 等: "用于未纯化蛋白样品核酸适配体筛选的Western印迹-SELEX筛选技术的建立", 生物技术通讯 * |
王琦 等: "基于核酸适配体传感器检测食品致病菌的研究进展", 生物技术通报 * |
Also Published As
Publication number | Publication date |
---|---|
CN114634934B (zh) | 2024-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11214794B2 (en) | Increasing dynamic range for identifying multiple epitopes in cells | |
Venkataramanan et al. | The Clostridium small RNome that responds to stress: the paradigm and importance of toxic metabolite stress in C. acetobutylicum | |
Fu et al. | Enzyme linked aptamer assay: based on a competition format for sensitive detection of antibodies to Mycoplasma bovis in serum | |
Ferreira et al. | Selection of peptidoglycan-specific aptamers for bacterial cells identification | |
US20210207128A1 (en) | Aptamer of nattokinase and method for screening the aptamer | |
CN101148667A (zh) | 一种亲和人白蛋白核酸适配子的制备与用途 | |
Gerovac et al. | The world of stable ribonucleoproteins and its mapping with Grad-seq and related approaches | |
CN114634934B (zh) | 特异识别金葡菌肠毒素b的核酸适配体3-2和2-27的序列及应用 | |
Li et al. | Recent developments in affinity-based selection of aptamers for binding disease-related protein targets | |
US9068216B2 (en) | Methods and devices for rapid detection and identification of live microorganisms by aptamers and/or antibodies immobilized on permeable membranes | |
CN110819632B (zh) | 用于结合曲妥珠抗体的核酸适体 | |
CN109628456B (zh) | 特异性识别粪肠球菌的ssDNA适配体 | |
CN109810980B (zh) | 一种特异识别酪胺的核酸适配体及其应用 | |
Ito et al. | In vitro selected oligonucleotides as receptors in binding assays | |
CN106636105B (zh) | 金黄色葡萄球菌肠毒素c2的核酸适配体c203及其筛选方法和应用 | |
CN116514987B (zh) | 一种抗cg7544蛋白的纳米抗体及编码基因和应用 | |
CN110885828B (zh) | 一种白喉毒素的核酸适配体dt01及其应用 | |
CN110923239B (zh) | 一种白喉毒素的核酸适配体dt04及其应用 | |
CN110885829B (zh) | 一种白喉毒素的核酸适配体dt05及其应用 | |
CN114438090B (zh) | 特异性结合布鲁氏菌外膜蛋白Omp31核酸适配体及其用途 | |
CN110904112B (zh) | 一种白喉毒素的核酸适配体dt03及其应用 | |
CN114807150B (zh) | 靶向和拮抗hmgb1分子的核酸适体 | |
CN113980970B (zh) | 与海葵溶细胞素gt-4特异性结合的适配体及其应用 | |
CN110938631A (zh) | 一种白喉毒素的核酸适配体dt02及其应用 | |
CN116769784A (zh) | 特异性识别庆大霉素的核酸适配体及其筛选方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |